Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Translational Vision Science & Technology|August 25, 2020
Quantifiable In Vivo Imaging Biomarkers of Retinal Regeneration by Photoreceptor Cell TransplantationYing V Liu, Simrat K Sodhi, Gilbert Xue, et al.
The Journal of Allergy and Clinical Immunology. Global|December 26, 2025
Inflammatory and fibrotic biomarkers in patients with atopic dermatitis treated with cendakimabJie Li, Coryandar Gilvary, Lu Gao, et al.
Experimental Eye Research|August 3, 2021
Characterization and allogeneic transplantation of a novel transgenic cone-rich donor mouse lineYing V Liu, Derek Teng, Gregory J Konar, et al.
Annals of Clinical and Translational Neurology|August 8, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosisBruce A C Cree, Rachel Maddux, Amit Bar-Or, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
American Journal of Obstetrics and Gynecology|June 24, 2024
Amniocentesis in pregnancies at or beyond 24 weeks: an international multicenter studyRoni Zemet, Mohamad Ali Maktabi, Alexandra Tinfow, et al.
The British Journal of Dermatology|December 11, 2025
Topical Steroid Withdrawal (TSW) Syndrome: Developing Diagnostic Criteria through a Modified Delphi MethodCynhia Hsu, Lily Guo, Derrick Adams, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Development of an image-guided non-vitrectomy subretinal access approach for trans-scleral cell and gene therapy deliveryMandeep S Singh, Shoujing Guo, Christopher B Toomey, et al.
American Journal of Human Genetics|September 10, 2025
Bi-allelic deleterious variants in SNAPIN, which encodes a retrograde dynein adaptor, cause a prenatal-onset neurodevelopmental disorderHammad Yousaf, Maayke A de Koning, Kamal Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Susan O'Brien, Ian W Flinn, et al.
Pageof 18